超基因医药 RARE
$15.43 −$0.14 (-0.90%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $15.43 0.00%
开盘$15.68
昨收$15.57
当日区间$15.12 – $15.97
成交量4.05M
市值$1.57B
市盈率（TTM）–
股息率–
财报
财报日平均波动±5.6%近16次财报
收涨次数6 / 1638% 的概率
最佳反应+14.3%
最差反应-12.7%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 4 Aug 2026 | After Market | ±19.6% | -3.41% | 符合区间 |
| 2026/Q1 | 5 May 2026 | After Market | ±8.8% | +3.68% | 符合区间 |
| 2025/Q4 | 12 Feb 2026 | After Market | ±8.4% | -12.68% | 超出定价预期 |
| 2025/Q3 | 4 Nov 2025 | After Market | ±11.4% | -1.82% | 符合区间 |
| 2025/Q2 | 5 Aug 2025 | After Market | ±9.3% | -3.01% | 符合区间 |
| 2025/Q1 | 6 May 2025 | After Market | ±18.5% | -4.68% | 符合区间 |
| 2024/Q4 | 13 Feb 2025 | After Market | ±13.8% | -2.37% | 符合区间 |
| 2024/Q3 | 5 Nov 2024 | After Market | ±14.0% | -3.18% | 符合区间 |
| 2024/Q2 | 1 Aug 2024 | After Market | ±11.6% | +14.31% | 超出定价预期 |
| 2024/Q1 | 2 May 2024 | After Market | ±9.8% | -1.04% | 符合区间 |
| 2023/Q4 | 15 Feb 2024 | After Market | ±15.0% | +5.75% | 符合区间 |
| 2023/Q3 | 2 Nov 2023 | After Market | ±10.6% | +6.09% | 符合区间 |
| 2023/Q2 | 3 Aug 2023 | After Market | ±20.0% | -8.79% | 符合区间 |
| 2023/Q1 | 4 May 2023 | After Market | ±11.3% | +3.08% | 符合区间 |
| 2022/Q4 | 16 Feb 2023 | After Market | ±13.8% | +10.03% | 符合区间 |
| 2022/Q3 | 2 Nov 2022 | After Market | ±12.5% | -5.96% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$214.00M+28.1% YoY
营业利润-$75.00M+30.6% YoY
净利润-$92.00M+20.0% YoY
摊薄每股收益-$0.90+23.1% YoY
自由现金流-$98.00M+12.5% YoY
经营现金流-$97.00M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率83.1%
营业利润率-73.6%
净利率-81.7%
资产收益率-45.6%
流动比率1.73
负债/资产比率122.5%
现金及投资$292.00M
净现金（净负债）$292.00M
暂无评论——快来第一个聊聊 RARE。